Verona Drug Patent Portfolio
Verona's Family Patents
Clinical Trials
Recent Clinical Trials by Verona:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2 |
| A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations | Universita di Verona | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Effect of Ensifentrine on Sputum Markers of Inflammation in COPD | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List